Reevaluating goals of insulin therapy: Perspectives from large clinical trials

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 41-56

  Riddle, Matthew C ^a   Yuen, Kevin C J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cardiovascular risk; Diabetes; Glycemic control; Goals; Insulin; Macrovascular; Microvascular; Tactics

Indexed keywords

CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; METFORMIN; SULFONYLUREA DERIVATIVE;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES IN ADULTHOOD; LIFESTYLE MODIFICATION; METABOLIC REGULATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 84860648425     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.03.003     Document Type: Review

References (69)

1. Meinert C.L., Knatterud G.L., Prout T.E., et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):789-830.
2. American Diabetes Association Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
3. American Diabetes Association Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1):S11-S63.
4. Milicevic Z., Raz I., Beattie S.D., et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008, 31(Suppl 2):S155-S160.
5. Saydah S., Tao M., Imperatore G., et al. GHb level and subsequent mortality among adults in the U.S. Diabetes Care 2009, 32:1440-1446.
6. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
7. Sung J., Song Y.M., Ebrahim S., et al. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009, 119:812-819.
8. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
9. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
10. United Kingdom Prospective Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
11. United Kingdom Prospective Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
12. Feingold K.R., Browner W.S., Siperstein M.D. Prospective studies of muscle capillary basement membrane width in prediabetics. J Clin Endocrinol Metab 1989, 69:784-789.
13. Williamson J.R., Kilo C. Vascular complications in diabetes mellitus. N Engl J Med 1980, 302:399-400.
14. The Diabetes Control and Complications Trial Research Group Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. The DCCT Research Group. Am J Med 1991, 90:450-459.
15. Wredling R., Levander S., Adamson U., et al. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia 1990, 33:152-157.
16. Wright A., Burden A.C., Paisey R.B., et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
17. Harris M.I., Klein R., Welborn T.A., et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992, 15:815-819.
18. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
19. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
20. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
21. Chew E.Y., Ambrosius W.T., Davis M.D., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
22. Gerstein H.C., Miller M.E., Genuth S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828.
23. Zoungas S., Patel A., Chalmers J., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
24. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
25. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
26. White N.H., Sun W., Cleary P.A., et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008, 126:1707-1715.
27. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
28. Lind M., Oden A., Fahlen M., et al. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010, 53:1093-1098.
29. Riddle M.C. Tactics for type II diabetes. Endocrinol Metab Clin North Am 1997, 26:659-677.
30. Koro C.E., Bowlin S.J., Bourgeois N., et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004, 27:17-20.
31. United Kingdom Prospective Study Group UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990, 39:905-912.
32. Brown J.B., Nichols G.A., Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004, 27:1535-1540.
33. Cheung B.M., Ong K.L., Cherny S.S., et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
34. Mann D.M., Woodward M., Ye F., et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med 2009, 169:1718-1720.
35. McWilliams J.M., Meara E., Zaslavsky A.M., et al. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of Medicare coverage. Ann Intern Med 2009, 150:505-515.
36. Ismail-Beigi F., Moghissi E., Tiktin M., et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011, 154:554-559.
37. Calles-Escandon J., Lovato L.C., Simons-Morton D.G., et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010, 33:721-727.
38. Gerstein H.C., Riddle M.C., Kendall D.M., et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99:34i-43i.
39. Arnolds S., Dellweg S., Clair J., et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.
40. Buse J.B., Bergenstal R.M., Glass L.C., et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
41. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
42. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
43. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655.
44. Vilsboll T., Rosenstock J., Yki-Jarvinen H., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
45. Riddle M., Frias J., Zhang B., et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007, 30:2794-2799.
46. Riddle M., Pencek R., Charenkavanich S., et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009, 32:1577-1582.
47. Fourlanos S., Dotta F., Greenbaum C.J., et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005, 48:2206-2212.
48. Borg H., Gottsater A., Landin-Olsson M., et al. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001, 86:3032-3038.
49. Gottsater A., Landin-Olsson M., Fernlund P., et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993, 16:902-910.
50. Zimmet P. Antibodies to glutamic acid decarboxylase in the prediction of insulin dependency. Diabetes Res Clin Pract 1996, 34(Suppl):S125-S131.
51. Davis T.M., Wright A.D., Mehta Z.M., et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005, 48:695-702.
52. The Diabetes Control and Complications Trial Research Group Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998, 128:517-523.
53. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008, 29:351-366.
54. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992, 13:415-431.
55. Garvey W.T., Olefsky J.M., Griffin J., et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
56. Ilkova H., Glaser B., Tunckale A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
57. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
58. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27:2597-2602.
59. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
60. Bartnik M., Ryden L., Ferrari R., et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2004, 25:1880-1890.
61. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144.
62. Chaudhuri A., Janicke D., Wilson M.F., et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004, 109:849-854.
63. Malmberg K., Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65.
64. Malmberg K., Ryden L., Hamsten A., et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996, 17:1337-1344.
65. Szabo Z., Arnqvist H., Hakanson E., et al. Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with type II diabetes. Clin Sci (Lond) 2001, 101:37-43.
66. Ceremuzynski L., Budaj A., Czepiel A., et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999, 13:191-200.
67. Mehta S.R., Yusuf S., Diaz R., et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005, 293:437-446.
68. Gerstein H., Yusuf S., Riddle M.C., et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008, 155:26-32. 32.e21-6.
69. Hippocrates Aphorisms. Hippocratic writings 1978, 206. Pelican Books Ltd., Middlesex (England). G.E.R. Lloyd (Ed.).